Capricor Therapeutics shares rose after the FDA resumed review of its Biologics License Application for Deramiocel, a cell therapy targeting Duchenne muscular dystrophy. The resubmission follows positive Phase 3 trial results, with the FDA setting a decision date of August 22, 2026.